73547-70-3
Chemical Structure
Ceftazidime dihydrochloride
Synonym(s): GR20263 dihydrochloride
- CAS No.: 73547-70-3
- Formula:C22H24Cl2N6O7S2
- Molecular Weight:619.50
IUPAC Name: 1-(((6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)pyridin-1-ium chloride hydrochloride
InChIKey: JLZLIGALAZXURA-ZYMGEXDGSA-N
SMILES: [O-]C(C1=C(C[N+]2=CC=CC=C2)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC(C)(C)C(O)=O)=O)([H])N1C3=O)=O.Cl.Cl
Biological Activity: Ceftazidime (GR20263) dihydrochloride is a cephalosporin β-lactam antibiotic. Ceftazidime dihydrochloride exhibits activity against susceptible Enterobacteriaceae, multidrug-resistant Gram-negative bacteria, Pseudomonas aeruginosa, and bacteria producing Ambler class A, C, and some class D β-lactamases, but shows no activity against microorganisms producing metallo-β-lactamases. Ceftazidime dihydrochloride reduces bacterial loads in mouse models of splenic, hepatic, and thigh infections, but has low efficacy against ESBL- and KPC-producing Enterobacteriaceae. Ceftazidime dihydrochloride can be used in research related to complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, carbapenemase-producing Klebsiella pneumoniae infections, carbapenem-resistant Enterobacterales infections, and severe Gram-negative bacterial infections[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ceftazidime dihydrochloride | Ceftazidime (GR20263) dihydrochloride is a cephalosporin β-lactam antibiotic. Ceftazidime dihydrochloride exhibits activity against susceptible Enterobacteriaceae, multidrug-resistant Gram-negative bacteria, Pseudomonas aeruginosa, and bacteria producing Ambler class A, C, and some class D β-lactamases, but shows no activity against microorganisms producing metallo-β-lactamases. Ceftazidime dihydrochloride reduces bacterial loads in mouse models of splenic, hepatic, and thigh infections, but has low efficacy against ESBL- and KPC-producing Enterobacteriaceae. Ceftazidime dihydrochloride can be used in research related to complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, carbapenemase-producing Klebsiella pneumoniae infections, carbapenem-resistant Enterobacterales infections, and severe Gram-negative bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sternbach N, et al. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis[J]. Journal of Antimicrobial Chemotherapy, 2018, 73(8): 2021-2029.
- [2]. van Duin D, et al. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations[J]. Clinical Infectious Diseases, 2016, 63(2): 234-241.
- [3]. Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae[J]. Antimicrobial Resistance & Infection Control, 2018, 7(1): 142.
- [4]. Lu G, et al. In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales. Infection and drug resistance. 2022;15:7107-7116. [Content Brief]
- [5]. MacVane SH, et al.. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrobial agents and chemotherapy. 2014 Nov;58(11):6913-9. [Content Brief]
